

Appendix 1: Equipotential Dose Comparison of Statins, 3 hydroxy-3-methyl-glutaryl-coenzyme A Reductase Inhibitors for Low Density Lipoprotein Reduction

% LDL Reduction	Simvastatin (Zocor)	Atorvastatin (Lipitor)	Rosuvastatin (Crestor)	Fluvastatin (Lescol)	Lovastatin (Mevacor)	Pravastatin (Pravachol)	Ezetimibe and Simvastatin (Vytorin)
Less than 24	5 mg	—	—	20 mg	10 mg	10 mg	—
25–32	10 mg	—	—	40 mg	20 mg	20 mg	—
31–39	20 mg	10 mg	—	80 mg	40 mg	40 mg	—
37–49	40 mg	20 mg	5 mg	—	80 mg	80 mg	10 and 10
49–52	80 mg	40 mg	10 mg	—	—	—	10 and 20
55–60	—	80 mg	20 mg	—	—	—	10 and 40
60–63	—	—	40 mg	—	—	—	10 and 80

LDL, low-density lipoprotein.

Data from Beth Smith ME, Lee NJ, Haney E, and Carson S. Drug class review: HMG-CoA reductase inhibitors (statins) and fixed-dose combination products containing a statin. Available at: <http://www.ncbi.nlm.nih.gov/books/NBK47273/>. Retrieved April 22, 2015.

Nevandusky NS, Arsdale AV, Strickler HD, Spoozak LA, Moadel A, Kaur G, et al. Association between statin use and endometrial cancer survival. *Obstet Gynecol* 2015;126.

The authors provided this information as a supplement to their article.

© Copyright 2015 American College of Obstetricians and Gynecologists.